A study to look at how safe different doses of MOXR0916 were for patients with cancer – when combined with one or two other medicines

A Study to Assess the Safety and Pharmacokinetics of MOXR0916 and Atezolizumab (Also Known as MPDL3280A or Anti-PD-L1) in Participants With Locally Advanced or Metastatic Solid Tumors

  • Cancer
  • Tumor
  • Neoplasms
  • Solid Tumors
Please note that the recruitment status of the trial at your site may differ from the overall study status because some study sites may recruit earlier than others.
Trial Status:

Completed

This trial runs in
Cities
  • Antwerpen
  • Aurora
  • Barcelona
  • Boston
  • Bruxelles
  • Camperdown
  • Chicago
  • Gent
  • Heidelberg
  • Madrid
  • Melbourne
  • Montréal
  • Nashville
  • Nedlands
  • New Haven
  • Pamplona
  • Scottsdale
  • Seattle
  • Seoul
  • Toronto
  • València
  • Vancouver
  • Villejuif
  • Washington
Trial Identifier:

NCT02410512 2015-000516-18 GO29674

      Show trial locations

      The source of the below information is public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc.. It has been summarised and edited into simpler language. For more information about this clinical trial see the For Expert tab on the specific ForPatients page or follow these links to https://clinicaltrials.gov and/or https://euclinicaltrials.eu and/or https://www.isrctn.com.

      The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.

      Results Disclaimer

      Trial Summary

      This Phase Ib, open-label, dose-escalation study will evaluate the safety, tolerability, and pharmacokinetics of the combination of MOXR0916 and atezolizumab in participants with locally advanced, recurrent, or metastatic incurable solid malignancy that has progressed after available standard therapy; or for which standard therapy has proven to be ineffective or intolerable or is considered inappropriate; or for which a clinical trial of an investigational agent is a recognized standard of care. Participants will be enrolled in two stages: a dose-escalation stage and an expansion stage.

      Genentech, Inc. Sponsor
      Phase 1 Phase
      NCT02410512, GO29674, 2015-000516-18 Trial Identifier
      All Gender
      ≥18 Years Age
      No Healthy Volunteers

      This clinical trial was done to study a new medicine called, “MOXR0916”, for the treatment of patients with cancer. This study was done to find out if MOXR0916 given with atezolizumab with and without bevacizumab – was safe for patients. Researchers also wanted to find out if the treatment had any effect on cancer. Two hundred and ninety-eight patients took part in this study at 25 study centers in 7 countries.

      Trial Summary

      This Phase Ib, open-label, dose-escalation study will evaluate the safety, tolerability, and pharmacokinetics of the combination of MOXR0916 and atezolizumab in participants with locally advanced, recurrent, or metastatic incurable solid malignancy that has progressed after available standard therapy; or for which standard therapy has proven to be ineffective or intolerable or is considered inappropriate; or for which a clinical trial of an investigational agent is a recognized standard of care. Participants will be enrolled in two stages: a dose-escalation stage and an expansion stage.

      Genentech, Inc. Sponsor
      Phase 1 Phase
      NCT02410512, GO29674, 2015-000516-18 Trial Identifier
      Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 [PD-L1] antibody, MOXR0916, a humanized agonist anti-OX40 monoclonal antibody Treatments
      Neoplasms Condition
      Official Title

      A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of MOXR0916 and Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors

      Eligibility Criteria

      All Gender
      ≥18 Years Age
      No Healthy Volunteers
      Inclusion Criteria
      • Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
      • Life expectancy of at least 12 weeks
      • Adequate hematologic and end organ function
      • Histologic documentation of locally advanced, recurrent, or metastatic incurable solid malignancy that has progressed after available standard therapy; or for which standard therapy is ineffective, intolerable, or considered inappropriate; or for which a clinical trial of an investigational agent is recognized standard of care
      • Tumor specimen availability
      • Measurable disease according to RECIST v1.1
      Exclusion Criteria
      • Any anti-cancer therapy, whether investigational or approved, including chemotherapy, hormonal therapy, or radiotherapy, within 3 weeks prior to initiation of study treatment
      • Malignancies other than disease under study within 5 years prior to D1 of C1
      • Primary central nervous system (CNS) malignancy, or untreated/active CNS metastases
      • History of leptomeningeal disease
      • History of idiopathic pulmonary fibrosis, pneumonitis (including drug-induced), organizing pneumonia, or evidence of active pneumonitis on screening chest computed tomography scan; history of radiation pneumonitis in the radiation field (fibrosis) is permitted
      • History of autoimmune disease
      • Positive human immunodeficiency virus test result
      • Active hepatitis B, hepatitis C, or tuberculosis
      • Severe infection within 4 weeks prior to D1 of C1
      • Prior allogeneic bone marrow or solid organ transplantation
      • Significant cardiovascular disease
      • Known clinically significant liver disease

      For the latest version of this information please go to www.forpatients.roche.com

       

      Related Trials

      Use our search to find other trials on Genentech Clinical Trials in related disease areas.

      Neoplasms Solid Tumors

      About Clinical Research

      What is a clinical trial? Why should I consider taking part in a clinical trial? And why does Genentech conduct clinical trials?

      Find out now